Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine
- PMID: 25953357
- PMCID: PMC4864658
- DOI: 10.1038/npp.2015.132
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine
Abstract
Some schizophrenia patients are more sensitive to amphetamine (AMPH)-induced exacerbations in psychosis-an effect that correlates with higher striatal dopamine release. This enhanced vulnerability may be related to gamma-aminobutyric acid (GABA) deficits observed in schizophrenia. We hypothesized that a pharmacologically induced GABA deficit would create vulnerability to the psychotomimetic effects to the 'subthreshold' dose of AMPH in healthy subjects, which by itself would not induce clinically significant increase in positive symptoms. To test this hypothesis, a GABA deficit was induced by intravenous infusion of iomazenil (IOM; 3.7 μg/kg), an antagonist and partial inverse agonist of benzodiazepine receptor. A subthreshold dose of AMPH (0.1 mg/kg) was administered by intravenous infusion. Healthy subjects received placebo IOM followed by placebo AMPH, active IOM followed by placebo AMPH, placebo IOM followed by active AMPH, and active IOM followed by active AMPH in a randomized, double-blind crossover design over 4 test days. Twelve healthy subjects who had a subclinical response to active AMPH alone were included in the analysis. Psychotomimetic effects (Positive and Negative Syndrome Scale (PANSS)), perceptual alterations (Clinician Administered Dissociative Symptoms Scale (CADSS)), and subjective effects (visual analog scale) were captured before and after the administration of drugs. IOM significantly augmented AMPH-induced peak changes in PANSS positive symptom subscale and both subjective and objective CADSS scores. There were no pharmacokinetic interactions. In conclusion, GABA deficits increased vulnerability to amphetamine-induced psychosis-relevant effects in healthy subjects, suggesting that pre-existing GABA deficits may explain why a subgroup of schizophrenia patients are vulnerable to AMPH.
Figures
Similar articles
-
Probing GABA receptor function in schizophrenia with iomazenil.Neuropsychopharmacology. 2011 Feb;36(3):677-83. doi: 10.1038/npp.2010.198. Epub 2010 Nov 10. Neuropsychopharmacology. 2011. PMID: 21068719 Free PMC article. Clinical Trial.
-
gamma-Aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation.Biol Psychiatry. 2006 Jan 15;59(2):128-37. doi: 10.1016/j.biopsych.2005.06.020. Epub 2005 Sep 2. Biol Psychiatry. 2006. PMID: 16140281 Clinical Trial.
-
GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.Neuropsychopharmacology. 2015 Jul;40(8):2047-56. doi: 10.1038/npp.2015.58. Epub 2015 Mar 2. Neuropsychopharmacology. 2015. PMID: 25728472 Free PMC article. Clinical Trial. No abstract available.
-
Long-lasting psychotomimetic consequences of repeated low-dose amphetamine exposure in rhesus monkeys.Neuropsychopharmacology. 1999 Jan;20(1):10-28. doi: 10.1016/S0893-133X(98)00050-5. Neuropsychopharmacology. 1999. PMID: 9885781
-
Human Laboratory Studies on Cannabinoids and Psychosis.Biol Psychiatry. 2016 Apr 1;79(7):526-38. doi: 10.1016/j.biopsych.2016.01.011. Epub 2016 Feb 2. Biol Psychiatry. 2016. PMID: 26970363 Review.
Cited by
-
Adderall-Induced Persistent Psychotic Disorder Managed With Long-Acting Injectable Haloperidol Decanoate.Cureus. 2022 Jul 26;14(7):e27273. doi: 10.7759/cureus.27273. eCollection 2022 Jul. Cureus. 2022. PMID: 36039224 Free PMC article.
-
Competitive Antagonism of Anesthetic Action at the γ-Aminobutyric Acid Type A Receptor by a Novel Etomidate Analog with Low Intrinsic Efficacy.Anesthesiology. 2017 Nov;127(5):824-837. doi: 10.1097/ALN.0000000000001840. Anesthesiology. 2017. PMID: 28857763 Free PMC article.
References
-
- Abel KM, Allin MP, Hemsley DR, Geyer MA (2003). Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44: 729–737. - PubMed
-
- Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761–767. - PubMed
-
- Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M (2009). Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biol Psychiatry 65: 1091–1093. - PubMed
-
- Abi-Saab W, Seibyl JP, D'Souza DC, Karper LP, Gueorgueva R, Abi-Dargham A et al (2002). Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology (Berl) 162: 55–62. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical